Shin Nippon Biomedical Laboratories : SNBL USA Announces Newly Appointed Experts to Acute Radiation Syndrome (ARS) Advisory Board
March 20, 2015 at 07:29 am
Share
Everett, WA - March 5, 2015 - SNBL USA, the experts in preclinical research, announced today the members of its newly-formed ARS Advisory Board, comprised of leading experts in the field of radiation biology and research. The Advisory Board will serve to provide strategic vision and scientific guidance to SNBL USA's ARS program.
"We are excited and honored to announce the formation of this Board as we broaden our ARS program," said Dr. Koichiro Fukuzaki, SNBL USA President and CEO. "These distinguished members represent years of technical and scientific expertise, providing immeasurable value to SNBL as we continue our commitment to lead the industry in this important area of research and development."
The members of SNBL USA's ARS Advisory Board include:
Nicholas Dainiak, MD, FACP, Clinical Professor of Medicine, Departments of Internal Medicine and Therapeutic Radiology, Yale University School of Medicine
George E. Georges, MD, Associate Member, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington
Martin Hauer-Jensen, MD, PhD, FACS, Professor of Pharmaceutical Sciences, Surgery, and Pathology, Director, Division of Radiation Health, Associate Dean for Research, College of Pharmacy, University of Arkansas for Medical Sciences
Alan Liss, PhD, pharmaceutical industry consultant, formerly a Director of the Medical Countermeasures Initiative in the Office of the Commissioner at the FDA
Thomas J. MacVittie, PhD, Professor, Radiation Oncology and Pathology, University of Maryland School of Medicine
John E. Moulder, PhD, Professor of Radiation Biology, Department of Radiation Oncology, Medical College of Wisconsin
"The formal launch of our ARS Advisory Board enforces our commitment to working with clients in the development of innovative treatments for various forms of ARS," said Dr. Ronald Manning, SNBL USA senior technical director of model development. "These highly respected and influential thought leaders in the radiation field will position SNBL USA to contribute in the development of vital ARS medical countermeasures."
For additional information regarding SNBL services and capabilities, contact us at +1.425.322.1950 or info@snblusa.com.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., SNBL USA offers a unique range of safety assessment services to fulfill its commitment to help free patients from suffering. Managed and operated by a team world renowned for its wide-ranging NHP experience and expertise, SNBL USA offers programs ranging from regulatory toxicology to customized study designs in multiple drug classes (biologics, small molecules, oligonucleotides, vaccines).
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.